Drug Profile
Research programme: GRB2 inhibitors - SUGEN
Alternative Names: GRB2 inhibitors research programme - SUGEN; Growth inhibitor factor receptor binding protein 2 inhibitors research programme - SUGENLatest Information Update: 28 Feb 2008
Price :
$50
*
At a glance
- Originator SUGEN
- Class
- Mechanism of Action Apoptosis stimulants; Signal transduction pathway inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 06 Apr 2000 Pharmacia & Upjohn has merged with Monsanto to form Pharmacia Corporation
- 21 Sep 1999 SUGEN has been acquired by Pharmacia & Upjohn
- 27 Nov 1998 Preclinical development for Cancer in USA (Unknown route)